---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-110412"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-09-24T20:16:39+00:00"
generated_at: "2026-09-24T20:17:23.027704+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rezolute FY26 net loss $77.6M; cash $107.8M; upLIFT positive, sunRIZE under FDA review

## Summary
- Cash and investments $107.8M at Jun 30, 2026, down from $167.9M at Jun 30, 2025.
- FY2026 net loss $77.6M vs $74.4M FY2025; Q4 net loss $20.5M vs $24.4M year ago.
- R&D FY26 $53.8M (down from $61.5M); G&A FY26 $29.2M (up from $18.4M).
- upLIFT Phase 3: 7 of 8 enrolled participants met primary endpoint responder criterion; topline results expected before end of 2026.
- sunRIZE Phase 3 congenital HI missed primary endpoint; data remains under FDA review; OLE ongoing with improved glycemic control.

## SEC filing metadata
- accession: 0001104659-26-110412
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-09-24T20:16:39+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/0001104659-26-110412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-110412
- JSON: https://secwatch.observer/filing/0001104659-26-110412.json
- Plain text: https://secwatch.observer/filing/0001104659-26-110412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.